Muthiah Vaduganathan, MD, MPH

Hosts discuss how recent advances in HFpEF have changed discussions surrounding how cardiologists should approach treatment sequencing.

Hosts break down the STRIDE and SOUL trial results and reflect on how they might inform treatment strategies in the respective patient populations.

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.

In this episode, Muthiah Vadugnathan, MD, MPH, and Stephen Greene, MD, discuss finerenone and MRA data from ESC Congress 2024.

Brendon Neuen, MBBS, PhD, joins the podcast to discuss the latest updates in nephrology, including the landmark FLOW trial.

In this ACC.24 episode of Don't Miss a Beat, hosts are joined by Javed Butler, MD, for a breakdown of the EMPACT-MI trial.

In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.

Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

Drs James Januzzi, Javed Butler, Robert Mentz, and Muthiah Vaduganathan share practice pearls for treating patients with heart failure, focusing on the future of treatment.

Robert Mentz, MD, reviews the results of the STONG-HF trial for patients in the hospital for heart failure.

Experts in cardiology comment on the impact of recent trials on heart failure with preserved ejection fraction (HFpEF) in clinical practice.

Muthiah Vaduganathan, MD, MPH, provides an overview of the pooled data from the PARAGLIDE-HF and PARAGON-HF clinical trials in heart failure.

Experts in cardiology discuss the use of sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF), highlighting the PARAGLIDE-HF study.

Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).

Robert J. Mentz, MD, reviews the current unmet needs for patients with heart failure, highlighting triple or quadruple therapy.

Javed Butler, MD, MPH, MBA, comments on implementing, continuing or cutting back on quadruple therapy after patient’s cardiac function has improved.

Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.

Javed Butler, MD, MPH, MBA, discussesSGLT-2 inhibitors and their use in heart failure.

Experts in cardiology highlight the four pillars of guideline directed therapies in heart failure.

Robert J. Mentz, MD, and James Januzzi, MD, discuss the key takeaways from updated heart failure guidelines, highlighting heart failure stages A and B.

Muthiah Vaduganathan, MD, MPH, and Javed Butler, MD, MPH, MBA, share approaches to treating patients with heart failure, focusing on patient education as well as social determinants of health.

Experts in cardiology review the classification of heart failure using left ventricle ejection fraction (EF).

Muthiah Vaduganathan, MD, MPH, comments on the impact of recurrent rehospitalizations for heart failure on survival.

Javed Butler, MD, MPH, MBA, and Robert J. Mentz, MD, review the current prevalence of heart failure in the US and Europe, as well as the clinical and economic challenges that arise with increasing prevalence.

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.

Don't Miss a Beat hosts are joined by Alexandre Mebazaa, MD, PhD, lead investigator of the STRONG-HF trial, to discuss the inspiration for the trial, its design, and important takeaways for those looking to implement a similar strategy of rapid, in-hospital uptitration of GDMT in heart failure at their own practice.

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.